Arthritis & Rheumatic Disease Specialties Miami, FL - 33180

Arthritis & Rheumatic Disease Specialties is categorized under Doctors in Miami, FL and active since 2008.

Arthritis & Rheumatic Disease Specialties was established in 2008, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Doctors business, which does work in the B2C market, and is classified as a Doctors, under code number 621111 by the NAICS.

If you are seeking more information, feel free to contact Norman B Gaylis at the company’s single location by writing to 21097 Ne 27th Court, Miami, Florida FL 33180 or by phoning (305) 652-6676. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Arthritis & Rheumatic Disease Specialties
Contact Person: Norman B Gaylis
Address: 21097 Ne 27th Court, Miami, Florida 33180
Phone Number: (305) 652-6676
Website Address: rheum-care.com
Annual Revenue (USD): $500.000 to $999.999
Founded: 2008
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Doctors
SIC Code: 8011
NAICS Code: 621111
Share This Business:

Arthritis & Rheumatic Disease Specialties was started in 2008 to provide professional Doctors under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact Norman B Gaylis for inquiries that concern Arthritis & Rheumatic Disease Specialties by calling the company number (305) 652-6676, as your correspondence is most welcome. Additionally, the physical location of the single location of Arthritis & Rheumatic Disease Specialties can be found at the coordinates 25.970648,-80.146502 as well as the street address 21097 Ne 27th Court in Miami, Florida 33180.

For its online presence, you may visit Arthritis & Rheumatic Disease Specialties’s website at rheum-care.com and engage with its social media outlets through on Twitter and on Facebook.